Metastatic melanoma: ESMO 2025 updates in 2 minutes

Three key clinical questions were addressed at ESMO 2025: the role of vaccines in first-line therapy, management of PD-1-resistant disease, and optimal treatment duration. Associate Professor Marco Donia, MD, PhD, University of Copenhagen & Clinician-Scientist at Herlev Hospital, Denmark, summarizes the main findings and their implications for treatment decisions in metastatic melanoma.